Analysts have set 12-month price targets for Avidity Biosciences, revealing an average target of $66.31, a high estimate of ...

The company plans to submit a Biologics Licence Application to the US Food and Drug Administration later in 2025 for its DMD ...

After some earlier data sparked questions from analysts, Avidity Biosciences has released more data for its RNA-based ...

Avidity Biosciences (RNA) announced del-zota topline data from the Phase 1/2 EXPLORE44 trial in people living with Duchenne muscular dystrophy ...

Needham & Company LLC reiterated their buy rating on shares of Avidity Biosciences (NASDAQ:RNA – Free Report) in a report ...

In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Avidity Biosciences (RNA – Research Report), with a price ...

Investment analysts at Citigroup began coverage on shares of Avidity Biosciences (NASDAQ:RNA – Get Free Report) in a research ...

While data on functional endpoints are still to come, Avidity Biosciences Inc. executives said the firm is moving ahead with ...

Fintel reports that on March 13, 2025, Citigroup initiated coverage of Avidity Biosciences (NasdaqGM:RNA) with a Buy ...

Analysts have recently evaluated Avidity Biosciences and provided 12-month price targets. The average target is $69.0, accompanied by a high estimate of $72.00 and a low estimate of $65.00. This ...

Building on success across its three clinical programs, Avidity is leading in rare neuromuscular diseases with a strong balance sheet to execute on a transformational 2025 Major milestones ...

The 2022 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of Avidity, or following a bona fide period of non-employment ...